Your Search Results

Treatment dilemmas in STEMI patients with multivessel disease

21 May 2025 – From EuroPCR 2025

Address treatment dilemmas in STEMI patients with multivessel disease through this session focused on imaging and physiology-guided revascularisation strategies. Learn optimal approaches for cases with CABG indications, and timing considerations for non-culprit vessel revascularisation during hospital admission or later stages, supported by illustrative clinical cases.

Did danger shock change my practice?

21 May 2025 – From EuroPCR 2025

Reflect on how contemporary management of cardiogenic shock has evolved through this session. Review collaborative strategies, challenging clinical cases involving STEMI, multivessel disease, refractory shock, spontaneous coronary artery dissection, and the critical role of intracoronary imaging in guiding interventional decisions.

Integrative step-by-step approach to perform successful CTO interventions: from angiographic evaluation to strategy selection

20 May 2025 – From EuroPCR 2025

Master the integrative step-by-step approach to successful chronic total occlusion (CTO) interventions. This session emphasizes systematic angiographic evaluation and strategy selection ranging from simple to complex techniques, supplemented by blinded case discussions for practical learning.

Integrative step-by-step approach to perform successful CTO interventions: from angiographic evaluation to strategy selection

Novelty in no-reflow management in STEMI patients

20 May 2025 – From EuroPCR 2025

Discover novel approaches to manage no-reflow phenomenon in STEMI patients. This session covers innovative therapies including the OPTI-STEMI trial strategies, mechanical thrombectomy, pharmacological interventions with Cangrelor, and super saturated oxygen therapy targeting coronary microcirculation preservation.

Novelty in no-reflow management in STEMI patients

5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)

01 Apr 2025

Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.